# Study of Efficacy and Safety of Myl1401O + Taxane vs Herceptin©+ Taxane for 1st Line, Met. Br. Ca.

> **NCT02472964** · PHASE3 · COMPLETED · sponsor: **Mylan Inc.** · enrollment: 500 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **BIOLOGICAL:** Trastuzumab
- **BIOLOGICAL:** MYL- 1401O
- **DRUG:** Paclitaxel
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT02472964
- **Lead sponsor:** Mylan Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07
- **Primary completion:** 2016-03
- **Final completion:** 2018-08
- **Target enrollment:** 500 (ACTUAL)
- **Last updated:** 2022-02-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02472964

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02472964, "Study of Efficacy and Safety of Myl1401O + Taxane vs Herceptin©+ Taxane for 1st Line, Met. Br. Ca.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02472964. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*